Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott's Hytrin HYCAT results show reduction in BPH treatment failures, cost effectiveness -- AUA meeting.

Executive Summary

ABBOTT's HYTRIN HYCAT STUDY REDUCES BPH TREATMENT FAILURES to 12.1% in patients with moderately severe symptoms compared to 24% for placebo-treated patients over a one-year period, according to results of the 2,084-patient trial presented April 24 at the American Urological Association annual meeting in Las Vegas. The randomized double-blind placebo-controlled Hytrin Community Assessment Trial conducted in 15 universities and 143 community-based sites collected data on efficacy of the alpha-1 blocker therapy in patients with benign prostatic hyperplasia over a one year period.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS026112

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel